trial
as of 2026-07-01Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
NCTId NCT00051298
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
107 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2002-11
Primary completion
—
Eligibility
ALL · 13 Years · 17 Years
Interventions & indications
Drugs
Indications
Sponsors
Eli Lilly and CompanyLead Sponsor
Investigators
1
Sites
25 total
Little Rock, United StatesCerritos, United StatesSan Diego, United StatesWashington D.C., United StatesJacksonville, United StatesNorth Miami, United StatesAtlanta, United StatesChicago, United StatesIndianapolis, United StatesLake Charles, United StatesBangor, United StatesMinneapolis, United States
Facts & assertions
3 sourced
Enrollment
107
Phase
PHASE3
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
indication
indication